|
BioScreening - organic compounds for screening
Drug Discovery Press ReleasesTosk, Inc. Reduces Submission Time and Cost for Drug Regulatory Filings With EXTEDO eCTDmanager Suite - WEST CHESTER, PA — 06/12/09 — EXTEDO, a key eSubmission solutions provider for life sciences firms, today announced that Tosk, Inc., a biopharmaceutical company dedicated to improving the safety of drugs marketed for debilitating and life-threatening diseases, is using the eCTDmanager Suite(TM) to reduce the time and cost of drug regulatory filings.
The EXTEDO eCTDmanager Suite [...]
Commonwealth Biotechnologies, Inc. Provides Market Update on Contemplated Acquisition of GL Biochem - RICHMOND, Va.–(BUSINESS WIRE)–Jun 11, 2009 - Commonwealth Biotechnologies, Inc. (“CBI”) (NASDAQ Capital Market:CBTE) is pleased to provide the following market update reporting on its recently executed term sheet to acquire all of the outstanding shares of GL Biochem (Shanghai) Ltd (“GL Biochem”).1. CBI MERGER WITH GL BIOCHEM
Following CBI’s announcement of June 8, 2009, CBI Management [...]
The Vaccines Development Conference September 23-25 2009 Boston MA, USA - The Vaccines Development Conference brings together scientists and industry experts from pharma, biotech, academia and government to share what’s working and not working for them, and to address your key vaccine development challenges and questions.
Novel Adjuvant Development: Hear current advances in novel adjuvants with discussions and case studies from National Cancer Institute, NIH, Big DNA, [...]
qPCR - Quantitive Polymerase Chain Reaction & Transcriptional Profiling - With increasing applications in research to provide sensitive quantitative measurements of gene expression, including SNP genotyping, mutation detection and quantification, and gene dosage studies, quantitative polymerase chain reaction technology (qPCR) could soon be the standard for determining the genetic changes in response to a pharmacological agent.
Topic Overview
* Biomarkers clinic
* Increasing through-put
* Solid Phase Gene Expression
* [...]
Clinical Trials Forum, 8th & 9th October 2009, Vienna, Austria - How successful are you in patient recruitment and retention? When & how to partner with CROs to achieve greater efficiency in clinical trials?
Now it’s time to focus on strategies and innovations for improving patient recruitment and retention. It is the largest cause of study delays. Join us & understand, when to start when optimizing patient [...]
Medical Devices in Europe, 17th & 18th September 2009, Vienna, Austria - The European region is composed of a diverse range of markets, all at different stages of development. Many of these markets exhibit fast growth rates, and the region as a whole is expected to grow. The inclusion of new member states into the European Union is opening up markets for medical devices. The member countries [...]
5th Annual Project & Portfolio Management in the Pharmaceutical Industry September 17-18 2009 Vienna, Austria - What is a balanced portfolio today? How do we ensure, that it’s going to be a balanced one tomorrow?
In current highly regulated and limited resources environment, it is crucial to understand, how to build an optimal mix of innovative projects within a portfolio, bring them forward quickly and manage them effectively.
Reveal new approaches and tools [...]
International Swine Flu Conference August 19-21 Washington DC - Top leaders and key decision-makers of major companies representing a broad range of industries will meet with distinguished scientists, public health officials, law enforcers, first responders, and other experts to discuss pandemic prevention, preparedness, response and recovery at the 1st International Swine Flu Summit.
At the summit, attendees will be able to draw on first-hand best [...]
TimTec Expands Partnership With Collaborative Drug Discovery Through Publishing Three Additional Libraries on CDD’s Free Public Access Database - Last October, TimTec and Collaborative Drug Discovery (CDD) established a collaboration in which CDD’s web-based data management system would host two TimTec Natural Products libraries on their free community Public Access site. Through this partnership, researchers would be able to register for a free account with CDD allowing them to chemically mine the contents of these TimTec [...]
3rd International Symposium on Advances in Synthetic and Medicinal Chemistry - Kiev, Ukraine, August 23 - 27, 2009
ASMC09 in Kiev is being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation, in the series of events which started with ASCMC04 Moscow followed by ASMC07 St. Petersburg.
Prof. Erick Carreira, ETH Zurich, Switzerland and Dr Scott Biller, Novartis Institutes for BioMedical Research, Cambridge, USA, have kindly [...]
Drug Discovery and Selection - 45e RICT - Orleans, France, July 1-3, 2009 - The upcoming edition of the RICT, the annual symposium of the Société de Chimie Thérapeutique (SCT), will be held in Orléans (France). This prestigious International Conference on Medicinal Chemistry will be organized by the University of Orléans and the Institute of Organic and Analytical Chemistry (ICOA).
Aim of the Symposium
The major change which has occurred in [...]
Clinical Trials in Asia Summit 2009 - st1\:* { BEHAVIOR: url(#ieooui) } @font-face { font-family: Verdana; } @page Section1 {size: 612.0pt 792.0pt; margin: 72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin: 35.4pt; mso-footer-margin: 35.4pt; mso-paper-source: 0; } P.MsoNormal { FONT-SIZE: 12pt; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: “Times New Roman”; mso-style-parent: “”; mso-pagination: widow-orphan; mso-fareast-font-family: “Times New Roman” } LI.MsoNormal { FONT-SIZE: 12pt; MARGIN: 0cm 0cm [...]
KINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex - Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis [...]
CLC bio’s enterprise platform wins award at Bio-IT World Expo in Boston - Boston, Massachusetts, USA — April 30, 2009 — CLC bio’s enterprise platform for Next Generation Sequencing data analysis, CLC Genomics Server, has just been awarded the “Best of Show” prize at the Bio-IT World Conference & Expo 2009 - an award judged by a team of Bio-IT World magazine editors and [...]
BioFocus DPI to apply TET Technology in high-throughput screening campaigns - Saffron Walden, UK and Heidelberg, Germany; 24 April 2009 – BioFocus DPI, a leading provider of gene-to-candidate discovery services, and TET Systems Holding, a privately-held, German-based biotech company, announced today that they have entered into an agreement to apply TET System’s inducible gene technology in high-throughput screening campaigns performed for BioFocus DPI customers.
[...]
AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting - In Vitro and In Vivo Data Show AEZS-126 as Promising Oral Compound for
Future Clinical Development in Cancer
QUEBEC CITY, April 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today presented two posters on AEZS-126, a promising compound for clinical intervention of the PI3K/ [...]
Discovery of dual function acridones as a new antimalarial chemotype - Preventing and delaying the emergence of drug resistance is an essential goal of antimalarial drug development. Monotherapy and highly mutable drug targets have each facilitated resistance, and both are undesirable in effective long-term strategies against multi-drug-resistant malaria. Haem remains an immutable and vulnerable target, because it is not parasite-encoded and its detoxification during haemoglobin degradation, [...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today
announced that it has identified a new lead for advancement in its
alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead
compound is from a program being evaluated as a potential treatment for
[...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today announced that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead compound is from a program being evaluated [...]
New Model For Drug Discovery With Fluorescent Anesthetic Demonstrated - ScienceDaily (Apr. 8, 2009) — A collaboration of University of Pennsylvania and University of Wisconsin chemists and anesthesiologists have identified a fluorescent anesthetic compound that will assist researchers in obtaining more precise information about how anesthetics work in the body and will provide a means to more rapidly test new anesthetic compounds in the search [...]
Sponsored Links
|
|
